Anthem Biosciences Ltd.
NSE: ANTHEM
Prev Close
592.5
Open Price
624
Volume
264,461
Today Low / High
597.35 / 624
52 WK Low / High
579.15 / 873.5
Range
577 - 638
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 607.4, with a change of 14.9 (2.51477%). The expected target range on the NSE is between 577 - 638. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
Anthem Biosciences Ltd. Graph
Anthem Biosciences Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Anthem Biosciences Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 607.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 607.40 | 613.47 | 552.13 - 674.82 |
| 619.55 | 495.64 - 743.46 | ||
| 625.62 | 437.94 - 813.31 | ||
| Bearish Scenario | 607.40 | 601.33 | 541.19 - 661.46 |
| 595.25 | 476.20 - 714.30 | ||
| 589.18 | 412.42 - 765.93 |
Overview of Anthem Biosciences Ltd.
ISIN
INE0CZ201020
Industry
Biotechnology
Vol.Avg
381,192
Market Cap
341,121,944,977
Last Dividend
0
Official Website
IPO Date
2025-07-21
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial income report data available. | |||||||||||
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial balance sheet data available. | ||||||||||||
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial cash flow statement data available. | |||||||||||
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 550.03 Cr | 223.36 Cr | 326.67 Cr | 0.5939 | 184.40 Cr | 173.43 Cr | 3.09 | 266.13 Cr | 0.3153 |
| 2024-09-30 | 524.96 Cr | 187.84 Cr | 337.11 Cr | 0.6422 | 175.24 Cr | 161.93 Cr | 2.88 | 223.08 Cr | 0.3085 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 503.83 Cr | 596.30 Cr | 1,100.13 Cr | 577.34 Cr | 185.76 Cr | 2,184.10 Cr | 1,029.47 Cr | 3,284.30 Cr | 531.75 Cr |
| 2025-03-31 | 316.14 Cr | 416.14 Cr | 732.28 Cr | 459.91 Cr | 340.43 Cr | 1,736.72 Cr | 1,007.43 Cr | 2,807.58 Cr | 397.72 Cr |
| 2024-09-30 | 214.35 Cr | 461.12 Cr | 675.47 Cr | 486.07 Cr | 363.87 Cr | 1,684.43 Cr | 914.52 Cr | 2,692.51 Cr | 488.14 Cr |
| 2024-03-31 | 183.86 Cr | 459.07 Cr | 642.93 Cr | 490.64 Cr | 211.35 Cr | 1,481.55 Cr | 837.71 Cr | 2,398.11 Cr | 473.46 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹372.30 | ₹479,941,925,883.00 | ₹4,837,855.00 |
| Anthem Biosciences Ltd. | ANTHEM | ₹607.40 | ₹341,121,944,977.00 | ₹264,461.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹161.23 | ₹213,366,523,645.00 | ₹3,828,528.00 |
| Syngene International Limited | SYNGENE | ₹478.00 | ₹192,037,352,752.00 | ₹1,991,386.00 |
| Onesource Specialty Pharma Ltd. | ONESOURCE | ₹1,177.60 | ₹134,935,460,864.00 | ₹394,328.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,164.10 | ₹121,783,723,076.00 | ₹139,740.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹666.35 | ₹105,290,553,220.00 | ₹363,382.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹421.30 | ₹73,080,983,553.00 | ₹500,242.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹693.25 | ₹55,794,701,100.00 | ₹157,567.00 |
| Zota Health Care Limited | ZOTA | ₹1,291.10 | ₹39,162,490,871.00 | ₹40,238.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹229.13 | ₹35,923,710,557.00 | ₹376,527.00 |
Key Executives
Gender: Not Specified
Year Born: 1965
Gender: male
Year Born: 1960
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1966
Gender: male
Year Born: 1968
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: female
Year Born:
FAQs about Anthem Biosciences Ltd.
The CEO is Ajay Bhardwaj.
The current price is ₹607.40.
The range is ₹579.15-873.5.
The market capitalization is ₹34,112.19 crores.
The P/E ratio is 101.66.
The company operates in the Healthcare sector.
Overview of Anthem Biosciences Ltd. (ISIN: INE0CZ201020) is a leading Biotechnology in India. With a market capitalization of ₹34,112.19 crores and an average daily volume of 381,192 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.